Monitoring immunogenicity of protein-based TNF antagonists

Frontline Gastroenterology

Volumn 7, Issue 2, 2016, Pages 152-154

  Bendtzen, Klaus ^a   Steenholdt, Casper ^b   Brynskov, Jørn ^b   Thomsen, Ole Ø ^b   Ainsworth, Mark A ^b  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIGEN ANTIBODY COMPLEX; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; BIOLOGICAL THERAPY; BLOOD SAMPLING; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; LETTER; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; TECHNOLOGY; TREATMENT RESPONSE;

EID: 84979925711     PISSN: 20414137     EISSN: 20414145     Source Type: Journal    
DOI: 10.1136/flgastro-2015-100596     Document Type: Letter

References (10)

1. Hendy P, Hart A, Irving P. Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Frontline Gastroenterol 2016;7: 122-8.
2. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med 2013;15:201-11.
3. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372: 196-203.
4. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
5. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81.
6. Afif W, Loftus EVJ, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
7. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349-58.
8. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87.
9. Sandborn WJ. Tailoring treatment to the individual patient: drug monitoring. Dig Dis 2014;32(Suppl 1):88-91.
10. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250-6.